Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04935359
Title Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

pancreatic ductal adenocarcinoma

Therapies

Gemcitabine + Nab-paclitaxel + NIS793

Gemcitabine + Nab-paclitaxel

Age Groups: adult | senior
Covered Countries USA | ESP | DEU | BEL

Additional content available in CKB BOOST